JiaRay Group is a multinational Pharmaceutical organization focused on developing novel anti-cancer therapies.
JiarRay Group engages every stage of the drug development process. Our family of companies harnesses tumor-targeted peptide-drug-conjugate technology to create novel oncology therapies and conducts clinical studies at top-tier cancer centers worldwide.
JiaRay Therapeutics, Inc. (USA)
San Diego-based JiaRay Therapeutics is conducting IND-enabling study and clinical development of JiaRay Group’s lead drug candidate, JR8603. Founded in 2016, the company also conducts drug design, in vitro & in vivo animal study design in biology, pharmacology, DMPK and toxicology.
JiaRay Biopharmaceuticals, Ltd. (China)
Founded in 2013, JiaRay biopharmaceuticals conducts all early-stage drug discovery activities in China.
JiaRay Pharmaceuticals, Inc. (Cayman Islands)
Founded in 2016, as holding company, the company owns worldwide rights of JiaRay Group outside of China.